AAAAAA
Results:
1-7
|
Results: 7
Authors:
GAYLOR DW
AXELRAD JA
BROWN RP
CAVAGNARO JA
CYR WH
HULEBAK KL
LORENTZEN RJ
MILLER MA
MULLIGAN LT
SCHWETZ BA
Citation: Dw. Gaylor et al., HEALTH RISK ASSESSMENT PRACTICES IN THE US FOOD-AND-DRUG-ADMINISTRATION, Regulatory toxicology and pharmacology, 26(3), 1997, pp. 307-321
Authors:
MORDENTI J
CAVAGNARO JA
GREEN JD
Citation: J. Mordenti et al., DESIGN OF BIOLOGICAL EQUIVALENCE PROGRAMS FOR THERAPEUTIC BIOTECHNOLOGY PRODUCTS IN CLINICAL DEVELOPMENT - A PERSPECTIVE, Pharmaceutical research, 13(10), 1996, pp. 1427-1437
Authors:
HENCK JW
HILBISH KG
SERABIAN MA
CAVAGNARO JA
HENDRICKX AG
AGNISH ND
KUNG AHC
MORDENTI J
Citation: Jw. Henck et al., REPRODUCTIVE TOXICITY TESTING OF THERAPEUTIC BIOTECHNOLOGY AGENTS, Teratology, 53(3), 1996, pp. 185-195
Authors:
CAVAGNARO JA
Citation: Ja. Cavagnaro, IMMUNOTOXICITY ASSESSMENT OF BIOTECHNOLOGY PRODUCTS - A REGULATORY POINT-OF-VIEW, Toxicology, 105(1), 1995, pp. 1-6
Authors:
KUNG AHC
CAVAGNARO JA
MAKIN A
WHITE MA
KONG KN
Citation: Ahc. Kung et al., TOXICOLOGIC EVALUATIONS OF AN IMMUNOTOXIN, H65-RTA, Fundamental and applied toxicology, 26(1), 1995, pp. 75-84
Authors:
BLACK LE
FARRELLY JG
CAVAGNARO JA
AHN CH
DEGEORGE JJ
TAYLOR AS
DEFELICE AF
JORDAN A
Citation: Le. Black et al., REGULATORY CONSIDERATIONS FOR OLIGONUCLEOTIDE DRUGS - UPDATED RECOMMENDATIONS FOR PHARMACOLOGY AND TOXICOLOGY STUDIES, Antisense research and development, 4(4), 1994, pp. 299-301
Authors:
GOLDENTHAL KL
CAVAGNARO JA
ALVING CR
VOGEL FR
Citation: Kl. Goldenthal et al., SAFETY EVALUATION OF VACCINE ADJUVANTS - PERATIVE-VACCINE-DEVELOPMENT-MEETING-WORKING-GROUP, AIDS research and human retroviruses, 9, 1993, pp. 190000047-190000051
Risultati:
1-7
|